RE:RE:RE:RE:RE:4,38C.....done....My answers: In general, all I'm stating is that price movement over timeframe and "new" facts should always be related given it's still a small cap and volatile; meaning it can get pushed both up and down over the short term quite a bit.
I just see that it's run very hard literally over a 5 hour trading period, so over a very short time. Had that rally of 15% happened over 5 days I wouldn't be highlighting it. Nothing has changed fundamentally. Technically it seems we do have more interest (a good thing) and they want it now rather than later. I get that. But we also know essentially what they are presenting at the AACR and it's not hard data in humans. They've stated it will be similar data to what was presented in TNBC and Ovarian but for pancreatic, endometial, colon and maybe melanoma (if that's done but it was always mentioned as something they were "testing"). Yes, good news, but we know from the basket study the numbers likely show very safe (low neutropenia) and ability to use high dosage, thus impact tumors far better. I'm not saying this isn't all great news and a reason to invest. I am positive on the what they'll learn in the trials and can't wait for that later in the year. I'm merely stating it's always been volatile on small volumes and likely will remain that way. This is all great movement, but it happened over a few hours so could retrace a bit. It won't stop the trend, just saying it may bounce in this new range for a bit without substantially new news.
FredTheVoice wrote: Your point of vue is interesting and reveals a legitimate concerne, but....
What if, actually, we are not even in a zone that we can call: "Fair value for TH shares".
For me, its not even a rally actually, even if it comes from traders.....and we know that large investors are joining the company's shareholder base.
Question for you, at what price actually would you think to yourself: "well, TH is way overvalued !". 8$ C ? 10$C ?
Ok lets say if the rally goes to 10$ C. I would be thinking: "Well, its a bit to much because we dont even know of oncology works in human !". So 8$C seems more raisonable.
BUT: if we have the news that NASH, with EMA and FDA in the plan, ....than : "Ok, I think 10$ C is a faire value..."
AND: this year, at the end of year: "TH reveals that oncology phase I is promising...."
Well, than : "12$C a share.....and maybe 16$ C a share is more a good target for the share price because that huge HUGE.
For me, the actual price is still way under-priced.
And the market is only making up for it.
FTV.